The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of piper methysticum

Sarris, J., Kavanagh, D; J., Byrne, G., Bone, K. M., Adams, J. and Deed, G. (2009) The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of piper methysticum. Psychopharmacology, 205 3: 399-407. doi:10.1007/s00213-009-1549-9


Author Sarris, J.
Kavanagh, D; J.
Byrne, G.
Bone, K. M.
Adams, J.
Deed, G.
Title The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of piper methysticum
Formatted title
The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of piper methysticum
Journal name Psychopharmacology   Check publisher's open access policy
ISSN 0033-3158
Publication date 2009-08-01
Year available 2009
Sub-type Article (original research)
DOI 10.1007/s00213-009-1549-9
Open Access Status Not Open Access
Volume 205
Issue 3
Start page 399
End page 407
Total pages 9
Editor H. de Wit
P. J. Cowen
Place of publication Germany
Publisher Springer
Language eng
Subject C1
110402 Naturopathy
111502 Clinical Pharmacology and Therapeutics
920410 Mental Health
920204 Evaluation of Health Outcomes
Abstract Piper methysticum (Kava) has been withdrawn in European, British, and Canadian markets due to concerns over hepatotoxic reactions. The WHO recently recommended research into "aqueous" extracts of Kava.
Formatted abstract
Rationale Piper methysticum (Kava) has been withdrawn in European, British, and Canadian markets due to concerns over hepatotoxic reactions. The WHO recently recommended research into “aqueous” extracts of Kava.
Objective The objective of this study was to conduct the first documented human clinical trial assessing the anxiolytic and antidepressant efficacy of an aqueous extract of Kava.
Design and participants The Kava Anxiety Depression Spectrum Study was a 3-week placebo-controlled, doubleblind crossover trial that recruited 60 adult participants with 1 month or more of elevated generalized anxiety. Five Kava tablets per day were prescribed containing 250 mg of kavalactones/day.
Results The aqueous extract of Kava reduced participants' Hamilton Anxiety Scale score in the first controlled phase by −9.9 (CI = 7.1, 12.7) vs. −0.8 (CI = −2.7, 4.3) for placebo and in the second controlled phase by −10.3 (CI = 5.8, 14.7) vs. +3.3 (CI = −6.8, 0.2). The pooled effect of Kava vs. placebo across phases was highly significant (p < 0.0001), with a substantial effect size (d = 2.24, n2p =  0:428). Pooled analyses also revealed highly significant relative reductions in Beck Anxiety Inventory and Montgomery–Asberg Depression Rating Scale scores. The aqueous extract was
found to be safe, with no serious adverse effects and no clinical hepatotoxicity.
Conclusions The aqueous Kava preparation produced significant anxiolytic and antidepressant activity and raised no safety concerns at the dose and duration studied. Kava appears equally effective in cases where anxiety is accompanied
by depression. This should encourage further study and consideration of globally reintroducing aqueous rootstock extracts of Kava for the management of anxiety.
Keyword Kava
Piper methysticum
Herbal medicine
Aqueous extract
Anxiety
Depression
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: 2010 Higher Education Research Data Collection
School of Public Health Publications
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 43 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 57 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 03 Sep 2009, 17:46:50 EST by Mr Andrew Martlew on behalf of Psychiatry - Royal Brisbane and Women's Hospital